Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic biologics, has declared the successful completion of patient enrollment for the Phase III clinical study of its vaccine candidate LZ901 in China. Over 98% of the participants have received the requisite two doses of either LZ901 injection or a placebo, as per the study’s protocol.
LZ901 is a recombinant herpes zoster vaccine that leverages the crystallizable region of the glycoprotein E fragment of the varicella zoster virus (VZV). Characterized by a tetramer molecular structure, LZ901 is intended to prevent herpes zoster infections caused by VZV. The Phase III study, which is multi-center, randomized, double-blind, and placebo-controlled, is designed to evaluate the protective efficacy and safety of LZ901 in preventing herpes zoster among adults aged 40 and above. The trial has successfully enrolled 26,000 healthy subjects within the specified age group.- Flcube.com
